Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
SkinBioTherapeutics ( (GB:SBTX) ) has shared an update.
SkinBioTherapeutics has signed an exclusive UK commercial agreement with Superdrug for its AxisBiotix™ products, marking a significant milestone as it enters the national high street market. To support this agreement and future product development, the company has raised £4.1 million through a placing and subscription, with an additional proposed retail offer to existing shareholders. The AxisBiotix-Ps product has also received the US National Psoriasis Foundation’s Seal of Recognition, enhancing its credibility and market potential in the USA.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
SkinBioTherapeutics’ overall stock score is primarily influenced by financial performance challenges, including net losses and cash flow issues. The technical analysis indicates bearish momentum, while valuation metrics are constrained by negative earnings. However, recent positive corporate events provide a potential for future improvement, offsetting some of the financial and technical concerns.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics plc is a life science group focused on skin health, specializing in products that alleviate symptoms of inflammatory skin conditions. The company is known for its AxisBiotix™ food supplements and is actively engaged in the skincare industry, with a market focus on innovative skin health solutions.
Average Trading Volume: 1,224,001
Technical Sentiment Signal: Hold
Current Market Cap: £40.38M
See more insights into SBTX stock on TipRanks’ Stock Analysis page.